{"id":"placebo-dispersible-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Placebo response (symptom improvement without active ingredient)"}]},"_chembl":{"chemblId":"CHEMBL635","moleculeType":"Small molecule","molecularWeight":"358.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo formulations are inert substances designed to mimic active drugs in appearance and administration route. In clinical trials, placebos serve as control comparators to isolate the true pharmacological effects of investigational drugs from psychological and contextual factors. The dispersible tablet formulation allows for flexible dosing and administration.","oneSentence":"A placebo dispersible tablet contains no active pharmaceutical ingredient and produces therapeutic effects through the placebo effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:52.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control arm (non-therapeutic use)"}]},"trialDetails":[{"nctId":"NCT06641466","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-03-11","conditions":"Menstrual Migraine","enrollment":723},{"nctId":"NCT04218084","phase":"PHASE3","title":"Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-11","conditions":"Sickle Cell Disease","enrollment":236},{"nctId":"NCT06616194","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-11-15","conditions":"Migraine","enrollment":200},{"nctId":"NCT07082543","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis","status":"RECRUITING","sponsor":"Azafaros A.G.","startDate":"2025-06-30","conditions":"Gangliosidoses, GM2, Gangliosidosis, GM1","enrollment":75},{"nctId":"NCT07082725","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)","status":"RECRUITING","sponsor":"Azafaros A.G.","startDate":"2025-06-30","conditions":"Niemann-Pick Type C Disease","enrollment":72},{"nctId":"NCT07054515","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis","status":"RECRUITING","sponsor":"Azafaros A.G.","startDate":"2025-06-30","conditions":"Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis","enrollment":147},{"nctId":"NCT07434271","phase":"PHASE2","title":"Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)","status":"RECRUITING","sponsor":"Kadence Bio","startDate":"2025-12-01","conditions":"Premature Ejaculation","enrollment":40},{"nctId":"NCT05165069","phase":"PHASE3","title":"The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-01-01","conditions":"Hand-foot Syndrome","enrollment":234},{"nctId":"NCT06561061","phase":"PHASE2, PHASE3","title":"Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2)","status":"COMPLETED","sponsor":"Indiana University","startDate":"2025-02-10","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT05810038","phase":"PHASE3","title":"A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-15","conditions":"Migraine","enrollment":787},{"nctId":"NCT06540833","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease","status":"RECRUITING","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2024-08-15","conditions":"Psychosis Associated With Alzheimer's Disease","enrollment":370},{"nctId":"NCT06651567","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia","status":"RECRUITING","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2024-10-22","conditions":"Agitation Associated With Alzheimer's Dementia","enrollment":320},{"nctId":"NCT07167316","phase":"PHASE1","title":"The Role of the LC-NA System in Experimental Sleep Fragmentation","status":"NOT_YET_RECRUITING","sponsor":"Hans-Peter Landolt","startDate":"2026-01-05","conditions":"The Role of the LC-NA System in Sleep Regulation","enrollment":42},{"nctId":"NCT05217927","phase":"PHASE4","title":"Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-04","conditions":"Migraine","enrollment":1415},{"nctId":"NCT06102044","phase":"PHASE3","title":"Zinc Supplementation for Young Infants With Clinical Severe Infection in Tanzania","status":"RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2024-12-27","conditions":"Neonatal Infection","enrollment":3250},{"nctId":"NCT05399485","phase":"PHASE3","title":"Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-09","conditions":"Migraine","enrollment":496},{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":2583},{"nctId":"NCT05418244","phase":"PHASE2, PHASE3","title":"Inhaled Isopropyl Alcohol for Treatment of Nausea","status":"RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2022-04-20","conditions":"Vomiting, Nausea, Children, Only","enrollment":84},{"nctId":"NCT07169162","phase":"PHASE4","title":"ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder","status":"WITHDRAWN","sponsor":"Aytu BioPharma, Inc.","startDate":"2019-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":""},{"nctId":"NCT06184399","phase":"PHASE2","title":"Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC","status":"COMPLETED","sponsor":"Jennifer Keiser","startDate":"2024-06-05","conditions":"Trichuriasis, Ascariasis, Hookworm Infections","enrollment":260},{"nctId":"NCT04866563","phase":"PHASE2","title":"A Study of Efficacy and Safety of AX-8 in Chronic Cough","status":"COMPLETED","sponsor":"Axalbion SA","startDate":"2021-08-11","conditions":"Chronic Cough","enrollment":108},{"nctId":"NCT05634746","phase":"PHASE3","title":"24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2022-12-29","conditions":"Eosinophilic Esophagitis","enrollment":218},{"nctId":"NCT06990776","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects","status":"WITHDRAWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-07-09","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT05020028","phase":"PHASE2, PHASE3","title":"Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-06-22","conditions":"Knee Arthritis","enrollment":100},{"nctId":"NCT05509400","phase":"PHASE4","title":"Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-10-18","conditions":"Migraine","enrollment":632},{"nctId":"NCT05518123","phase":"PHASE4","title":"Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-11-07","conditions":"Migraine","enrollment":658},{"nctId":"NCT04502966","phase":"PHASE2","title":"Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-11-09","conditions":"Allergic Rhinoconjunctivitis, Grass Pollen Allergy","enrollment":108},{"nctId":"NCT06992674","phase":"PHASE2","title":"The R-E-V-I-V-A-L Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-06-01","conditions":"Vestibular Migraine","enrollment":240},{"nctId":"NCT06748664","phase":"PHASE2","title":"A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-06-01","conditions":"Vestibular Migraine, Adults 18 Years and Older (no Other Exclusion Criteria)","enrollment":240},{"nctId":"NCT06964711","phase":"PHASE1","title":"GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects","status":"COMPLETED","sponsor":"Beijing Greatway Pharmaceutical Technology Co.,Ltd.","startDate":"2021-07-12","conditions":"Major Depressive Disorder","enrollment":92},{"nctId":"NCT05248997","phase":"PHASE3","title":"Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-02-17","conditions":"Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps","enrollment":261},{"nctId":"NCT05399459","phase":"PHASE3","title":"Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-09","conditions":"Migraine","enrollment":897},{"nctId":"NCT03475693","phase":"EARLY_PHASE1","title":"A Cohort Study Evaluating the Efficacy of PO Magnesium in the Treatment of Acute Traumatic Brain Injury in Adolescents","status":"COMPLETED","sponsor":"Corewell Health South","startDate":"2017-09-01","conditions":"Concussion Post Syndrome","enrollment":17},{"nctId":"NCT06150014","phase":"PHASE1, PHASE2","title":"A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12-07","conditions":"Chronic Hepatitis b","enrollment":88},{"nctId":"NCT04547842","phase":"EARLY_PHASE1","title":"Mirtazapine Versus Dexamethasone in Preventing Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-09-01","conditions":"Post Operative Nausea and Vomiting","enrollment":90},{"nctId":"NCT06566248","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-03-20","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT05127486","phase":"PHASE4","title":"A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-12-06","conditions":"Migraine, Episodic Migraine","enrollment":580},{"nctId":"NCT00812006","phase":"PHASE3","title":"A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-03-24","conditions":"Migraine","enrollment":108},{"nctId":"NCT05262517","phase":"PHASE3","title":"Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-05-05","conditions":"Temporomandibular Disorders (TMD)","enrollment":126},{"nctId":"NCT00894556","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-06-10","conditions":"Acute Migraine","enrollment":109},{"nctId":"NCT01001234","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-11-30","conditions":"Migraine, Acute","enrollment":1382},{"nctId":"NCT00516737","phase":"PHASE3","title":"Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-10-03","conditions":"Migraine","enrollment":207},{"nctId":"NCT00604812","phase":"PHASE1","title":"Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-17","conditions":"Migraine Disorders","enrollment":31},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":103},{"nctId":"NCT04574362","phase":"PHASE3","title":"Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-10-22","conditions":"Acute Migraine","enrollment":1648},{"nctId":"NCT04395365","phase":"PHASE3","title":"Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis","status":"UNKNOWN","sponsor":"University College, London","startDate":"2019-06-30","conditions":"Spontaneous Bacterial Peritonitis","enrollment":442},{"nctId":"NCT05083312","phase":"PHASE3","title":"Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2021-09-30","conditions":"Eosinophilic Esophagitis","enrollment":6},{"nctId":"NCT04281108","phase":"PHASE3","title":"Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)","status":"COMPLETED","sponsor":"Ellodi Pharmaceuticals, LP","startDate":"2020-01-30","conditions":"Eosinophilic Esophagitis","enrollment":143},{"nctId":"NCT03191864","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)","status":"COMPLETED","sponsor":"Adare Pharmaceuticals, Inc.","startDate":"2017-06-22","conditions":"Eosinophilic Esophagitis","enrollment":106},{"nctId":"NCT04672252","phase":"PHASE2, PHASE3","title":"The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-12-01","conditions":"Pain, Postoperative","enrollment":100},{"nctId":"NCT03461757","phase":"PHASE3","title":"Trial in Adult Subjects With Acute Migraines","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-02-27","conditions":"Migraine, With or Without Aura","enrollment":1811},{"nctId":"NCT03246620","phase":"PHASE4","title":"Oral Olanzapine Versus Haloperidol or Diazepam","status":"TERMINATED","sponsor":"The University of Hong Kong","startDate":"2017-09-01","conditions":"Acute Agitation, Behavioural Emergency","enrollment":12},{"nctId":"NCT03201419","phase":"PHASE2","title":"A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2017-07-27","conditions":"Nocturia","enrollment":302},{"nctId":"NCT00250458","phase":"PHASE3","title":"Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03","conditions":"Migraine","enrollment":346},{"nctId":"NCT04768478","phase":"PHASE4","title":"CBD for Pain Reduction and Opioid Use After Ankle and Tibia Fracture ORIF","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2021-10-01","conditions":"Ankle Fractures, Tibia Fracture","enrollment":""},{"nctId":"NCT02428647","phase":"NA","title":"Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2015-09","conditions":"Diarrhea","enrollment":3433},{"nctId":"NCT03758885","phase":"PHASE3","title":"Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2019-01-10","conditions":"Infertility","enrollment":820},{"nctId":"NCT02678195","phase":"PHASE4","title":"3 Days Versus 5 Days Amoxicillin for Chest-indrawing Childhood Pneumonia in Malawi","status":"COMPLETED","sponsor":"Save the Children","startDate":"2016-03","conditions":"Pneumonia","enrollment":3000},{"nctId":"NCT02760420","phase":"PHASE4","title":"3 Days Amoxicillin Versus Placebo for Fast Breathing Childhood Pneumonia in Malawi","status":"COMPLETED","sponsor":"Save the Children","startDate":"2016-06","conditions":"Pneumonia","enrollment":1126},{"nctId":"NCT03528434","phase":"NA","title":"Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS)","status":"COMPLETED","sponsor":"Indiana University","startDate":"2019-03-14","conditions":"Sickle Cell Disease","enrollment":250},{"nctId":"NCT04728984","phase":"PHASE3","title":"A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet","status":"UNKNOWN","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2020-09-07","conditions":"Uremic Pruritus","enrollment":135},{"nctId":"NCT04706377","phase":"NA","title":"Vitamin B12 Supplementation in Diabetic Neuropathy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2018-02-01","conditions":"Diabetes Mellitus, Diabetic Neuropathies, Diabetic Complication","enrollment":90},{"nctId":"NCT04531865","phase":"PHASE3","title":"Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2021-01-01","conditions":"Frequently Relapsing Nephrotic Syndrome, Steroid-Dependent Nephrotic Syndrome","enrollment":""},{"nctId":"NCT00940602","phase":"PHASE2","title":"Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03-22","conditions":"Myelodysplastic Syndromes","enrollment":225},{"nctId":"NCT03406793","phase":"NA","title":"Zinc-MNP Trial for Prevention of Diarrhea and Promotion of Linear Growth","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2018-02-20","conditions":"Diarrhea, Stunting","enrollment":2886},{"nctId":"NCT03110458","phase":"PHASE2","title":"Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy","status":"COMPLETED","sponsor":"Sensorion","startDate":"2017-08-16","conditions":"Acute Unilateral Vestibulopathy (AUV)","enrollment":107},{"nctId":"NCT03081208","phase":"PHASE3","title":"Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2017-03-06","conditions":"Infertility","enrollment":810},{"nctId":"NCT02278328","phase":"EARLY_PHASE1","title":"MEG Study of Acute STX209 Effects in ASD","status":"COMPLETED","sponsor":"Timothy Roberts","startDate":"2016-02","conditions":"Autism Disorder","enrollment":25},{"nctId":"NCT02905682","phase":"PHASE3","title":"Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-09","conditions":"Nocturia","enrollment":190},{"nctId":"NCT02904759","phase":"PHASE3","title":"Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-09","conditions":"Nocturia","enrollment":342},{"nctId":"NCT01713946","phase":"PHASE3","title":"A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04-29","conditions":"Tuberous Sclerosis Complex-associated Refractory Seizures","enrollment":366},{"nctId":"NCT03051009","phase":"PHASE3","title":"Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2017-01-11","conditions":"Nocturia","enrollment":503},{"nctId":"NCT01729819","phase":"PHASE2","title":"Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2013-01","conditions":"Overactive Bladder","enrollment":106},{"nctId":"NCT03196375","phase":"PHASE2","title":"A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.","status":"TERMINATED","sponsor":"Flex Pharma, Inc.","startDate":"2017-07-28","conditions":"Motor Neuron Disease","enrollment":54},{"nctId":"NCT03254199","phase":"PHASE2","title":"A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.","status":"TERMINATED","sponsor":"Flex Pharma, Inc.","startDate":"2017-10-16","conditions":"Charcot-Marie-Tooth Disease","enrollment":27},{"nctId":"NCT01870635","phase":"PHASE4","title":"Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in EDs in Pakistan","status":"COMPLETED","sponsor":"Dr. Stephen Freedman","startDate":"2014-05","conditions":"Dehydration, Gastroenteritis, Vomiting","enrollment":625},{"nctId":"NCT01870648","phase":"PHASE4","title":"Ondansetron Administration to Children With Gastroenteritis, Vomiting and SOME Dehydration in EDs in Pakistan","status":"COMPLETED","sponsor":"Dr. Stephen Freedman","startDate":"2014-05","conditions":"Dehydration, Gastroenteritis, Vomiting","enrollment":918},{"nctId":"NCT01835548","phase":"PHASE3","title":"NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Neos Therapeutics, Inc","startDate":"2013-07","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":87},{"nctId":"NCT02326142","phase":"PHASE2","title":"A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth","status":"TERMINATED","sponsor":"ObsEva SA","startDate":"2015-03","conditions":"Preterm Labor","enrollment":10},{"nctId":"NCT02310802","phase":"PHASE2","title":"OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI","status":"COMPLETED","sponsor":"ObsEva SA","startDate":"2014-11","conditions":"Infertility","enrollment":247},{"nctId":"NCT00907985","phase":"PHASE1","title":"A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-05-15","conditions":"Bipolar Disorder","enrollment":12},{"nctId":"NCT01552343","phase":"PHASE3","title":"Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2012-03","conditions":"Nocturia","enrollment":56},{"nctId":"NCT00944853","phase":"NA","title":"Effects of Liquid Zinc Supplementation and Dispersible Zinc Tablets on Plasma Zinc Concentration","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2009-08","conditions":"Zinc Deficiency","enrollment":462},{"nctId":"NCT01602510","phase":"PHASE3","title":"Lamotrigine Phase III Study in Bipolar I Disorder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08","conditions":"Bipolar Disorder","enrollment":265},{"nctId":"NCT01262456","phase":"PHASE3","title":"Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2011-02","conditions":"Nocturia","enrollment":395},{"nctId":"NCT01223937","phase":"PHASE3","title":"Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2010-11","conditions":"Nocturia","enrollment":268},{"nctId":"NCT01306266","phase":"NA","title":"Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2011-02","conditions":"Chronic Post-traumatic Headache","enrollment":""},{"nctId":"NCT01779466","phase":"PHASE2","title":"Daytime Impact Sleep Study","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2013-04","conditions":"Nocturia","enrollment":5},{"nctId":"NCT01487395","phase":"PHASE1","title":"Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2011-12","conditions":"Alzheimer Disease, Battery","enrollment":30},{"nctId":"NCT00934492","phase":"PHASE3","title":"Cotrimoxazole Prophylaxis in Severely Malnourished Children","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-11","conditions":"Nutrition Disorders, Life-threatening Infection","enrollment":1781},{"nctId":"NCT01348880","phase":"PHASE1","title":"Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-05","conditions":"Erectile Dysfunction","enrollment":42},{"nctId":"NCT01684800","phase":"PHASE2","title":"Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2012-09","conditions":"Nocturia","enrollment":178},{"nctId":"NCT01694498","phase":"PHASE2","title":"Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2012-09","conditions":"Nocturia","enrollment":183},{"nctId":"NCT01282268","phase":"PHASE3","title":"Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome","status":"COMPLETED","sponsor":"Seaside Therapeutics, Inc.","startDate":"2011-05","conditions":"Fragile X Syndrome","enrollment":125},{"nctId":"NCT00983151","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculation","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2009-08","conditions":"Premature Ejaculation","enrollment":1050},{"nctId":"NCT00983736","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2009-10","conditions":"Premature Ejaculation","enrollment":1050},{"nctId":"NCT00515320","phase":"PHASE3","title":"Study of Fluoxetine in Autism","status":"COMPLETED","sponsor":"Neuropharm","startDate":"2007-08","conditions":"Autistic Disorder","enrollment":158}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"Placebo dispersible tablet","genericName":"Placebo dispersible tablet","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo dispersible tablets are used in clinical trials for various conditions, including diarrhea, stunting, myelodysplastic syndromes, migraine disorders, and Niemann-Pick Type C disease. The mechanism of action of Placebo dispersible tablets is not directly related to their use in these trials, as they are classified as a glucocorticoid receptor agonist small molecule.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}